insights_auto
Por que 688235 subiu 4,06%?
Saiba maischevron_right
688235:SHA
BeOne Medicines AG
CN¥ 255,98
arrow_upward
+4,06%(+9,99) 1D
16 de out., 15:00:00 GMT+8 · CNY
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 688235…
Abrir
CN¥ 253,20
Alta
CN¥ 268,18
Baixa
CN¥ 252,09
Valor de mercado
289,03 bi
Volume médio
2,81 mi
Volume
5,69 mi
Índice P/L
91,43
Alto — 52 sem
CN¥ 319,24
Baixo — 52 sem
CN¥ 205,51
LPA
CN¥ 2,80
Nº de funcionários
12 mil
Abrir
CN¥ 253,20
Alta
CN¥ 268,18
Baixa
CN¥ 252,09
Valor de mercado
289,03 bi
Volume médio
2,81 mi
Volume
5,69 mi
Índice P/L
91,43
Alto — 52 sem
CN¥ 319,24
Baixo — 52 sem
CN¥ 205,51
LPA
CN¥ 2,80
Nº de funcionários
12 mil
Notícias
De fontes da web e parceiros de notícias
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Sobre BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Funcionários12 mil
Data de fundação28 de out. de 2010
Sede-
Setor-